Stay updated with breaking news from Nasdaq Rlmd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report) CEO Sergio Traversa bought 31,541 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The stock was purchased at an average price of $3.71 per share, with a total value of $117,017.11. Following the completion of the purchase, the chief executive officer […]
Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report) CFO Maged Shenouda bought 6,875 shares of the company’s stock in a transaction dated Wednesday, January 31st. The shares were purchased at an average price of $4.06 per share, with a total value of $27,912.50. Following the completion of the acquisition, the chief financial officer now owns […]
Parsons Capital Management Inc. RI increased its stake in shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD – Free Report) by 11.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 974,082 shares of the company’s stock after purchasing an additional 100,770 shares during the quarter. Parsons […]
Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report) was the target of a large decrease in short interest in December. As of December 15th, there was short interest totalling 638,800 shares, a decrease of 26.2% from the November 30th total of 865,800 shares. Based on an average daily volume of 172,800 shares, the days-to-cover ratio […]
Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD – Free Report) by 17.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 338,945 shares of the company’s stock after purchasing an additional 49,999 shares during the quarter. […]